The Effect of AST-120, Absorbent of Uremic Toxins on The Severity of Cardiac Failure in Patient with Chronic Heart Failure

Not Applicable

• Conditions: Chronic heart failure with chronic renal failure

• Registration Number: JPRN-UMIN000033876
• Lead Sponsor: AST-HF study office

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-09-01
• Study Completion: 2022-02-15
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with an allergic history of AST-120 2) Patients already treated with AST-120 3) Patients with stage 5 CKD 4) Patients suspected or diagnosed with Nephrotic syndrome 5) Patients using mechanical circulatory support devices 6) Patients waiting for heart transplant 7) Patients waiting for cardiac surgery 8) Patients with New York Heart Association (NYHA) Functional Classification, class III or IV at baseline 9) Patients with any past histories of acute coronary syndrome or coronary intervention or cardiac surgery developed within 6 months 10) Patients who start cardiac resynchronization therapy within 6 months 11) Patients who start beta blocker treatment within 6 months 12) Patients who start or change some drugs for heart failure or diabetes within 3 months 13) Patients expected to live less than 3 years 14) Patients with possible alcohol or drug abuse 15) Patients who are pregnant or possibly pregnant 16) Patients with breast feeding 17) Patients with disorder of gastrointestinal transit 18) Patients with gastrointestinal ulcer or esophageal varix 19) Patients who are prone to constipation 20) Patients who have been enrolled in other clinical studies at the same time with this study (excluding observational studies such as registry studies) 21) Patients who are judged by the investigator or subinvestigators to be not suitable for participation in the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes of plasma B-type natriuretic peptide concentration for 6 months from the baseline